{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:48:12Z","timestamp":1763765292606},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2775,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:p><jats:bold>Background.<\/jats:bold>  <jats:italic>Helicobacter pylori<\/jats:italic> eradication usually fails when clarithromycin is used against resistant strains.<\/jats:p><jats:p><jats:bold>Objective.<\/jats:bold> The objective of this study was to test whether the apparent synergy found in vitro between ranitidine bismuth citrate (RBC) and clarithromycin also exists in vivo against resistant strains.<\/jats:p><jats:p><jats:bold>Methods.<\/jats:bold>  <jats:italic>H. pylori<\/jats:italic> was cultured and clarithromycin susceptibility was determined before and after treatment, from duodenal ulcer patients receiving RBC and clarithromycin or omeprazole and clarithromycin for 2 weeks in a multicenter randomized clinical trial.<\/jats:p><jats:p><jats:bold>Results.<\/jats:bold> The overall eradication rate was 88.7% in the RBC group (71 patients) and 52.7% in the omeprazole group (74 patients). The demographic characteristics of the two groups were not different. Clarithromycin\u2010resistant strains were isolated in 22 cases (15.1%). A difference between the eradication rates of susceptible and resistant strains was found in the omeprazole group but not in the RBC group. After treatment, resistance to clarithromycin developed in three of the seven strains (42.3%) cultured from the patients of the RBC group, compared with 11 of the 26 strains (42%) of the omeprazole group. That is, clarithromycin\u2010resistant strains were found in 6% and 27% in the RBC group and the omeprazole group, respectively, on considering the global results.<\/jats:p><jats:p><jats:bold>Conclusion.<\/jats:bold> A synergy between RBC and clarithromycin may exist in vivo and, while clarithromycin resistance is increasing, it is an argument for using RBC in triple therapies.<\/jats:p>","DOI":"10.1046\/j.1523-5378.2000.00034.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:22:12Z","timestamp":1047424932000},"page":"222-226","source":"Crossref","is-referenced-by-count":21,"title":["Ranitidine Bismuth Citrate Can Help to Overcome <i>Helicobacter pylori<\/i> Resistance to Clarithromycin In Vivo"],"prefix":"10.1111","volume":"5","author":[{"given":"Francis","family":"M\u00e9graud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1991.tb01452.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199506001-00006"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199506001-00007"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00003.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1993.tb00094.x"},{"issue":"1","key":"e_1_2_6_7_2","first-page":"A12","article-title":"Ranitidine bismuth citrate can overcome in vitro antibiotic resistance in Helicobacter pylori.","volume":"41","author":"Midolo PD","year":"1997","journal-title":"Gut"},{"key":"e_1_2_6_8_2","first-page":"A1057","article-title":"Ranitidine bismuth citrate enhances clarithromycin activity against clinical isolates of H. pylori.","volume":"112","author":"Osato MS","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00572.x"},{"issue":"1","key":"e_1_2_6_10_2","first-page":"A1","article-title":"Cut\u2010off point for 13\u2010urea breath test.","volume":"39","author":"Johnston BJ","year":"1996","journal-title":"Gut"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs0930003"},{"issue":"1","key":"e_1_2_6_12_2","first-page":"A55","article-title":"Pre\u2010 and post\u2010treatment clarithromycin resistance of Helicobacter pylori strains: a key factor of treatment failure.","volume":"37","author":"Cayla R","year":"1995","journal-title":"Gut"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199601000-00008"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00223.x"},{"issue":"1","key":"e_1_2_6_15_2","first-page":"A90","article-title":"Prospective assessment of the impact of primary antimicrobial resistances on cure rates of Helicobacter pylori infections.","volume":"41","author":"Kist M","year":"1997","journal-title":"Gut"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00646.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70119-8"},{"key":"e_1_2_6_18_2","first-page":"A99","article-title":"H. pylori resistance to macrolides increases, to imidazoles remains stable.","volume":"112","author":"De Koster E","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)80952-9"},{"issue":"2","key":"e_1_2_6_20_2","first-page":"A11","article-title":"Survey of the in vitro susceptibility of Helicobacter pylori to antibiotics in France. Preliminary results.","volume":"43","author":"Broutet N","year":"1998","journal-title":"Gut"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)93181-8"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.41.2.207"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.116287000.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(98)00281-0"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00202.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00270.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00367.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(98)00281-0"}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1523-5378.2000.00034.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1523-5378.2000.00034.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1523-5378.2000.00034.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1523-5378.2000.00034.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T11:25:23Z","timestamp":1694431523000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1523-5378.2000.00034.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["10.1046\/j.1523-5378.2000.00034.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1523-5378.2000.00034.x","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}